Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 8/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5576752 | 0.87 | HDAC6 (0.70) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL5576186 | 0.83 | ADORA3 (0.69) | VDRMAPTSMN1; SMN2PGRADORA3 | |
| SCHEMBL7571453 | 0.82 | VDR (0.57) | VDRMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL7571458 | 0.82 | VDR (0.57) | VDRMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5685230 | 0.78 | VDR (0.52) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL5681058 | 0.78 | VDR (0.53) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL5573995 | 0.78 | VDR (0.67) | VDRMAPTSMN1; SMN2PGRADORA3 | |
| SCHEMBL5575681 | 0.78 | HDAC6 (0.59) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL6035758 | 0.74 | VDR (0.53) | VDR | |
| SCHEMBL5572947 | 0.74 | VDR (0.53) | VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210327-B1 | NEW VITAMIN D DERIVATIVES WITH CYCLIC SUBSTRUCTURES IN THE SIDE CHAINS, METHOD AND INTERMEDIATES FOR THEIR PRODUCTION AND THEIR USE IN THE PREPARATION OF MEDICAMENTS | SCHERING AG (DE) | 2006-01-18 | — | — | EP | claimed |
| US-20030149006-A1 | New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents | STEINMEYER ANDREAS (US) | 2003-08-07 | — | — | US | claimed |
| US-20070093448-A1 | Complexes that consist of vitamin D compounds or analogs thereof with a 5Z,7E,10(19)-triene system and methylated derivatives of beta-cyclodextrin | SCHERING AG (DE) | 2007-04-26 | — | — | US | disclosed |
| US-7115758-B2 | Vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents | SCHERING AG (DE) | 2006-10-03 | — | — | US | disclosed |
| EP-1210327-B1 | NEW VITAMIN D DERIVATIVES WITH CYCLIC SUBSTRUCTURES IN THE SIDE CHAINS, METHOD AND INTERMEDIATES FOR THEIR PRODUCTION AND THEIR USE IN THE PREPARATION OF MEDICAMENTS | SCHERING AG (DE) | 2006-01-18 | — | — | EP | disclosed |
| EP-1362848-A1 | Process for the preparation of vitamin D derivatives | Schering Aktiengesellschaft (DE) | 2003-11-19 | — | — | EP | disclosed |
| US-20030149006-A1 | New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents | STEINMEYER ANDREAS (US) | 2003-08-07 | — | — | US | disclosed |
| US-6603031-B1 | Active metabolites of vitamin D2 and vitamin D3 and their synthetic derivatives have a proliferation- inhibiting and differentiation-stimulating action on tumor cells and normal cells, | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149006-A1 | New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents | CYP24A1, CYP2R1, VDR | VDR 3/4885HDAC6 3613/4885HDAC3 2650/4885 |
| US-20070093448-A1 | Complexes that consist of vitamin D compounds or analogs thereof with a 5Z,7E,10(19)-triene system and methylated derivatives of beta-cyclodextrin | VDR, CYP24A1, CYP2R1 | VDR 1/4885HDAC6 2080/4885HDAC3 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.